KR20230058045A - 코로나바이러스 감염을 치료 및 예방하기 위한 방법 및 조성물 - Google Patents

코로나바이러스 감염을 치료 및 예방하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20230058045A
KR20230058045A KR1020237003077A KR20237003077A KR20230058045A KR 20230058045 A KR20230058045 A KR 20230058045A KR 1020237003077 A KR1020237003077 A KR 1020237003077A KR 20237003077 A KR20237003077 A KR 20237003077A KR 20230058045 A KR20230058045 A KR 20230058045A
Authority
KR
South Korea
Prior art keywords
ace2
cov
coronavirus
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003077A
Other languages
English (en)
Korean (ko)
Inventor
제임스 토르치아
고든 제이. 프리먼
Original Assignee
다나-파버 캔서 인스티튜트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다나-파버 캔서 인스티튜트 인크. filed Critical 다나-파버 캔서 인스티튜트 인크.
Publication of KR20230058045A publication Critical patent/KR20230058045A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237003077A 2020-07-20 2021-07-20 코로나바이러스 감염을 치료 및 예방하기 위한 방법 및 조성물 Pending KR20230058045A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053817P 2020-07-20 2020-07-20
US63/053,817 2020-07-20
US202163150686P 2021-02-18 2021-02-18
US63/150,686 2021-02-18
PCT/US2021/042372 WO2022020353A2 (en) 2020-07-20 2021-07-20 Methods and compositions for treatment and prevention of coronavirus infection

Publications (1)

Publication Number Publication Date
KR20230058045A true KR20230058045A (ko) 2023-05-02

Family

ID=77301019

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003077A Pending KR20230058045A (ko) 2020-07-20 2021-07-20 코로나바이러스 감염을 치료 및 예방하기 위한 방법 및 조성물

Country Status (8)

Country Link
US (1) US20230272359A1 (https=)
EP (1) EP4182458A2 (https=)
JP (1) JP2023535695A (https=)
KR (1) KR20230058045A (https=)
CN (1) CN116171324A (https=)
AU (1) AU2021312238A1 (https=)
CA (1) CA3189732A1 (https=)
WO (1) WO2022020353A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CA3185230A1 (en) * 2020-07-06 2022-01-13 Shengjiang Liu Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
US20230374153A1 (en) * 2022-04-13 2023-11-23 Paradigm Immunoterapeutics, Inc. METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2
CN119265271B (zh) * 2024-12-09 2025-04-22 上海益诺思生物技术股份有限公司 一种评价ade效应的系统及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
WO2000070032A1 (en) * 1999-05-13 2000-11-23 Zymogenetics, Inc. Zace2: a human metalloenzyme
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
SG10201602394QA (en) * 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
TW201402611A (zh) * 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
HK1214652A1 (zh) * 2013-03-13 2016-07-29 克里蒂科斯有限责任公司 用於检测胰腺癌的方法和组合物
CN107207594B (zh) * 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
WO2021183404A1 (en) * 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
CN113444710A (zh) * 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途
WO2021202427A2 (en) * 2020-03-29 2021-10-07 R-Pharm Overseas, Inc. Ace2-derived composition and use thereof
JP2023526540A (ja) * 2020-05-22 2023-06-21 フォーマイコン アーゲー Ａｃｅ２融合タンパク質及びその使用方法

Also Published As

Publication number Publication date
JP2023535695A (ja) 2023-08-21
US20230272359A1 (en) 2023-08-31
WO2022020353A3 (en) 2022-03-10
WO2022020353A2 (en) 2022-01-27
EP4182458A2 (en) 2023-05-24
CA3189732A1 (en) 2022-01-27
AU2021312238A1 (en) 2023-02-23
CN116171324A (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
KR20230058045A (ko) 코로나바이러스 감염을 치료 및 예방하기 위한 방법 및 조성물
JP7735373B2 (ja) 多鎖キメラポリペプチドおよびその使用
JP6621741B2 (ja) Ｃｔｌａ−４に対する親和性が改善したｃｄ８６バリアント
CN115244077B (zh) 蛋白质治疗剂
US20100249022A1 (en) Strategy for cloning and expressing the extracellular domains of receptors as soluble proteins
CN115836087A (zh) 抗cd26蛋白及其用途
CN110088131B (zh) 抗chikv抗体及其用途
AU2012322445B2 (en) Canine/feline CD20 binding epitope and compositions for binding thereto
Wines et al. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
US20230310584A1 (en) Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
TW202228765A (zh) 重組ACE2-Fc融合分子以及製造與使用其的方法
EP4335870A1 (en) Peptide therapeutics against sars-cov-2 spike protein
TWI916895B (zh) 多鏈嵌合多肽及其用途
HK40113400A (zh) Pd-1抗体及其用途
CN117659181A (zh) 针对sars-cov-2刺突蛋白的肽治疗剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240719

Comment text: Request for Examination of Application